0
Correspondence |

ResponseResponse FREE TO VIEW

Jong Sun Park, MD; Sei-Won Lee, MD; Jae-Joon Yim, MD
Author and Funding Information

From the Division of Pulmonary and Critical Care Medicine (Dr Park), Department of Internal Medicine, Seoul National University Bundang Hospital; Department of Pulmonary and Critical Care Medicine (Dr Lee), Asan Medical Center, University of Ulsan College of Medicine; and Division of Pulmonary and Critical Care Medicine (Dr Yim), Department of Internal Medicine, Seoul National University College of Medicine.

Correspondence to: Jae-Joon Yim, MD, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, 101 Daehangno, Jongno-gu, Seoul 110-744, South Korea; e-mail: yimjj@snu.ac.kr


Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be dis­cussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2012;142(6):1688-1689. doi:10.1378/chest.12-1439
Text Size: A A A
Published online
To the Editor:

We thank Dr Aggarwal and colleagues for their interest in and valuable comments on two of our publications.1,2 Their first comment addressed the article on the high rates of conversion and reversion in monthly interferon-γ release assay (IGRA) results for health-care workers.1 They asked whether any participant with a positive IGRA subsequently developed active TB, which is an important issue. So far, none of the participants has developed active TB. We plan to screen participants for active TB at 1, 2, and 5 years. Their second comment addressed another article describing the change in IGRA results among participants taking medication to treat latent TB infection.2 They asked what is meant by negative conversion of the IGRA with treatment of latent TB infection. Unfortunately, the clinical meaning of such conversions is not clear, and long-term follow-up is required to answer the question.

References

Park JS, Lee JS, Kim MY, et al. Monthly follow-ups of interferon-γ release assays among health-care workers in contact with patients with TB. Chest. 2012;142(6):1461-1468.
 
Lee SW, Lee SH, Yim JJ. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection. 2012;40(4):431-435. [CrossRef] [PubMed]
 

Figures

Tables

References

Park JS, Lee JS, Kim MY, et al. Monthly follow-ups of interferon-γ release assays among health-care workers in contact with patients with TB. Chest. 2012;142(6):1461-1468.
 
Lee SW, Lee SH, Yim JJ. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection. 2012;40(4):431-435. [CrossRef] [PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543